Scot Cave Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), a biomedical device company focusing on innovative medical devices for companion animals, has appointed Scot Cave as its new Field Veterinary Business Development Manager for the Northwest Region of the United States. Cave brings over 25 years of animal health sales and management experience to PetVivo, including leadership roles in the U.S. Army and positions with veterinary companies like Covetrus, Medivet, KindredBio, and Merck.
CEO John Lai expressed confidence that Cave's expertise will help PetVivo meet its primary objective of expanding sales. Cave, who holds a Bachelor of Science in Biology from Ferris State University, is enthusiastic about promoting Spryng, PetVivo's veterinary medical device that addresses joint-related afflictions by targeting cartilage loss or damage rather than just treating symptoms.
PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), un'azienda di dispositivi biomedici che si concentra su innovativi dispositivi medici per animali domestici, ha nominato Scot Cave come nuovo Manager dello Sviluppo Commerciale Veterinario sul Campo per la regione del Nord-Ovest degli Stati Uniti. Cave porta con sé oltre 25 anni di esperienza nelle vendite e nella gestione della salute animale a PetVivo, inclusi ruoli di leadership nell'Esercito degli Stati Uniti e posizioni presso aziende veterinarie come Covetrus, Medivet, KindredBio e Merck.
Il CEO John Lai ha espresso fiducia che l'expertise di Cave aiuterà PetVivo a raggiungere il suo obiettivo principale di espandere le vendite. Cave, che possiede una laurea in Biologia presso la Ferris State University, è entusiasta di promuovere Spryng, il dispositivo medico veterinario di PetVivo che affronta le afflizioni articolari mirando alla perdita o al danno della cartilagine piuttosto che limitarsi a trattare i sintomi.
PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), una empresa de dispositivos biomédicos que se centra en dispositivos médicos innovadores para animales de compañía, ha designado a Scot Cave como su nuevo Gerente de Desarrollo Comercial Veterinario de Campo para la región del Noroeste de los Estados Unidos. Cave aporta más de 25 años de experiencia en ventas y gestión de salud animal a PetVivo, incluyendo roles de liderazgo en el Ejército de los Estados Unidos y puestos en empresas veterinarias como Covetrus, Medivet, KindredBio y Merck.
El CEO John Lai expresó confianza en que la experiencia de Cave ayudará a PetVivo a cumplir su objetivo principal de expandir las ventas. Cave, que posee una licenciatura en Biología de la Ferris State University, está entusiasmado por promover Spryng, el dispositivo médico veterinario de PetVivo que aborda las afecciones articulares al enfocarse en la pérdida o daño del cartílago en lugar de solo tratar los síntomas.
PetVivo Holdings, Inc. (OTCQB: PETV & PETVW)는 반려동물에 대한 혁신적인 의료 기기에 초점을 맞춘 생물 의학 기기 회사로서, 스콧 케이브를 미국 북서부 지역의 새로운 현장 수의학 비즈니스 개발 관리자로 임명했습니다. 케이브는 25년 이상의 동물 건강 영업 및 관리 경험을 PetVivo에 제공하며, 미국 육군의 리더십 역할과 Covetrus, Medivet, KindredBio, Merck와 같은 수의학 회사의 직책을 역임했습니다.
CEO 존 라이(John Lai)는 케이브의 전문성이 PetVivo가 판매 확장을 목표로 하는 데 도움이 될 것이라고 확신했습니다. 생물학에서 학사 학위를 가진 케이브는 증상만을 치료하기 보다는 연골 손실이나 손상을 겨냥하여 관절 관련 질환을 해결하는 PetVivo의 수의학 의료 기기인 Spryng을 홍보하는 것에 대해 열정적입니다.
PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), une entreprise de dispositifs biomédicaux spécialisée dans des dispositifs médicaux innovants pour les animaux de compagnie, a nommé Scot Cave comme nouveau Responsable du Développement Commercial Vétérinaire sur le Terrain pour la région du Nord-Ouest des États-Unis. Cave apporte à PetVivo plus de 25 ans d'expérience dans les ventes et la gestion de la santé animale, y compris des rôles de leadership dans l'armée américaine et des postes dans des entreprises vétérinaires telles que Covetrus, Medivet, KindredBio et Merck.
Le PDG John Lai a exprimé sa confiance que l'expertise de Cave aidera PetVivo à atteindre son objectif principal d'expansion des ventes. Cave, qui possède un Bachelor of Science en biologie de la Ferris State University, est enthousiaste à l'idée de promouvoir Spryng, le dispositif médical vétérinaire de PetVivo qui traite les affections articulaires en ciblant la perte ou les dommages du cartilage plutôt qu'en se contentant de traiter les symptômes.
PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), ein biomedizinisches Unternehmen, das sich auf innovative medizinische Geräte für Haustiere konzentriert, hat Scot Cave als neuen Leiter für die Geschäftsentwicklung im veterinärmedizinischen Außendienst für die Nordwestregion der Vereinigten Staaten ernannt. Cave bringt über 25 Jahre Erfahrung im Verkauf und Management im Bereich Tiergesundheit zu PetVivo, darunter Führungsrollen in der US-Armee und Positionen bei veterinärmedizinischen Unternehmen wie Covetrus, Medivet, KindredBio und Merck.
CEO John Lai äußerte Vertrauen, dass Caves Expertise PetVivo helfen wird, das Hauptziel der Verkaufssteigerung zu erreichen. Cave, der einen Bachelor of Science in Biologie von der Ferris State University hat, ist begeistert davon, Spryng, das veterinärmedizinische Gerät von PetVivo, zu fördern, das Gelenkerkrankungen adressiert, indem es sich auf den Verlust oder die Schädigung des Knorpels konzentriert, anstatt nur die Symptome zu behandeln.
- Appointment of experienced Field Veterinary Business Development Manager for Northwest Region
- New hire brings over 25 years of animal health sales and management experience
- Potential for sales expansion in the Northwest Region
- Addition of leadership experience to the sales team
- None.
MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States.
"The addition of Scot to our sales and distribution team provides our company a wealth of leadership and veterinary sales experience,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “One of our primary objectives to achieve success in our company is to expand sales; we believe that the vast insight and expertise Scot brings to the PetVivo Sales Team puts us in an excellent position to meet this objective”
Scot Cave brings to PetVivo more than 25 years of animal health sales and management experience. He brings a wealth of leadership experience which began with his professional career as an officer in the United States Army. Most recently Scot achieved success while working as a Regional Veterinary Account Manager with our distribution partner Covetrus. Additionally, Scot’s career has provided valuable sales experience in veterinary industry positions with veterinary companies, such as Medivet, KindredBio and Merck, to just name a few. Scot has a Bachelor of Science degree in Biology, with a minor in General Science/Chemistry from Ferris State University in Big Rapids, Michigan.
“Joining PetVivo as a new Field Veterinary Business Development Manager is an incredible opportunity for me to continue my passion, leverage my industry knowledge, and positively impact the quality of life for horses and companion animals. I am excited and honored to be a part of this valuable team,” said Scot Cave. “I am thankful for the opportunity to be able to promote and sell a veterinary medical device that addresses joint related afflictions caused by the loss or damage of cartilage rather than simply treating the symptoms of pain and inflammation. I truly believe Spryng has the ability to improve the medical outcomes of animals suffering from lameness and other joint related afflictions, such as osteoarthritis, thereby enhancing the lives of animals and their owners.”
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact
FAQ
Who is the new Field Veterinary Business Development Manager for PetVivo Holdings (PETV)?
What experience does Scot Cave bring to PetVivo Holdings (PETV)?
What is the main product Scot Cave will be promoting at PetVivo Holdings (PETV)?
What is PetVivo Holdings' (PETV) primary objective according to the press release?
